RKDA

+ Watchlist + Portfolio

Arcadia Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.44
52-Week Range: $0.38 – $6.71
Market Cap: $1.11M
P/E (TTM): —
EPS (TTM): -4.72
Dividend Yield: —

Advanced Metrics

Price/Book: 1.59
PEG Ratio: —
Return on Equity: -430.93%
Return on Assets: -34.76%
Gross Margin: 34.60%
Operating Margin: -34.37%
Profit Margin: -234.53%
Current Ratio: 3.49
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $345.50K
Revenue Growth: -0.80%
Earnings Growth: —
Enterprise Value: $-3.06M

RKDA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$7.42M	$4.45M	$5.04M	$4.86M
Cost of Revenue	$6.10M	$2.17M	$2.96M	$3.10M
Gross Profit	$1.32M	$2.28M	$2.08M	$1.76M
Research & Development	$1.51M	$64.00K	$53.00K	$9.00K
Selling, General & Admin	$15.04M	$8.23M	$9.64M	$7.00M
Operating Expenses	$16.55M	$8.30M	$9.69M	$11.76M
Operating Income	-$15.23M	-$6.02M	-$7.61M	-$9.99M
EBITDA	-$14.75M	-$5.73M	-$7.50M	-$9.96M
Pretax Income	-$10.81M	-$5.32M	-$4.31M	-$2.33M
Income Tax	$14.00K	$8.00K	$8.00K	$8.00K
Net Income	-$15.38M	-$13.98M	-$7.04M	-$2.34M
Diluted EPS	-25.65	-11.29	-5.17	-1.71
Diluted Shares	599389	1.24M	1.36M	1.37M

RKDA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.64M	$6.52M	$4.24M	$259.00K
Receivables	$1.22M	$506.00K	$3.07M	$425.00K
Inventory	$2.32M	$837.00K	$904.00K	$1.21M
Current Assets	$25.40M	$14.97M	$9.24M	$6.36M
Total Assets	$28.92M	$19.70M	$13.52M	$6.55M
Current Liabilities	$4.21M	$3.59M	$2.56M	$2.06M
Total Debt	$2.02M	$1.01M	$155.00K	$0.00
Total Liabilities	$8.02M	$7.00M	$7.29M	$2.41M
Retained Earnings	-$257.86M	-$271.84M	-$278.88M	-$281.22M
Shareholders' Equity	$21.03M	$12.84M	$6.22M	$4.14M
Working Capital	$21.19M	$11.38M	$6.68M	$4.30M

RKDA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.98M	-$15.29M	-$9.63M	-$4.74M
Capital Expenditure	-$72.00K	-$5.00K	-$16.00K	—
Free Cash Flow	-$14.05M	-$15.30M	-$9.64M	-$4.74M
Depreciation & Amortisation	$479.00K	$287.00K	$113.00K	$32.00K
Stock-Based Compensation	$1.11M	$717.00K	$512.00K	$234.00K
Investing Cash Flow	$1.42M	-$4.34M	$7.34M	$750.00K
Financing Cash Flow	$4.52M	$5.51M	$9.00K	$6.00K
Net Change in Cash	-$8.04M	-$14.13M	-$2.28M	-$3.98M

RKDA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$1.20M	$1.46M	$1.30M	$901.00K	$1.10M
Cost of Revenue	$682.00K	$824.00K	$884.00K	$709.00K	$700.00K
Gross Profit	$518.00K	$631.00K	$418.00K	$192.00K	$400.00K
Research & Development	$0.00	$9.00K	$0.00	$0.00	—
Selling, General & Admin	$1.74M	$2.12M	$1.57M	$1.57M	$1.18M
Operating Expenses	$1.74M	$6.62M	$1.83M	$1.57M	$1.18M
Operating Income	-$1.22M	-$5.99M	-$1.41M	-$1.38M	-$779.00K
EBITDA	-$1.21M	-$5.97M	-$1.41M	-$1.37M	-$771.00K
Pretax Income	$2.60M	-$4.46M	$856.00K	-$1.33M	-$4.38M
Net Income	$2.60M	-$4.46M	$856.00K	-$1.34M	-$4.38M
Diluted EPS	1.90	-3.26	0.62	—	-2.11
Diluted Shares	1.37M	1.37M	1.37M	—	2.08M

RKDA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.16M	$1.38M	$1.12M	$259.00K	$954.00K
Receivables	$3.58M	$1.26M	$831.00K	$425.00K	$425.00K
Inventory	$1.28M	$1.49M	$1.46M	$1.21M	$840.00K
Current Assets	$8.85M	$7.58M	$8.39M	$6.36M	$5.17M
Total Assets	$12.99M	$7.79M	$8.58M	$6.55M	$5.32M
Current Liabilities	$2.22M	$1.84M	$2.29M	$2.06M	$1.36M
Total Debt	$21.00K	$11.00K	$0.00	$0.00	—
Total Liabilities	$4.08M	$3.25M	$3.14M	$2.41M	$2.44M
Retained Earnings	-$276.28M	-$280.74M	-$279.88M	-$281.22M	-$285.60M
Shareholders' Equity	$8.90M	$4.53M	$5.44M	$4.14M	$2.88M
Working Capital	$6.63M	$5.74M	$6.10M	$4.30M	$3.80M

RKDA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.59M	-$2.03M	-$257.00K	-$861.00K	-$1.10M
Free Cash Flow	-$1.59M	-$2.03M	-$257.00K	-$861.00K	-$1.10M
Depreciation & Amortisation	$13.00K	$15.00K	$2.00K	$2.00K	$8.00K
Stock-Based Compensation	$78.00K	$86.00K	$53.00K	$17.00K	$15.00K
Investing Cash Flow	$500.00K	$250.00K	$0.00	$0.00	$0.00
Financing Cash Flow	$5.00K	$0.00	$1.00K	$0.00	$1.79M
Net Change in Cash	-$1.08M	-$1.78M	-$256.00K	-$861.00K	$695.00K

Market Snapshot

About

Arcadia Biosciences is an agricultural technology company focused on developing and commercializing crop productivity traits and nutritional oils. The company uses advanced breeding and biotechnology techniques to improve crop yield, quality, and environmental sustainability. Arcadia develops wheat, soybean, and canola varieties with enhanced nutritional profiles and agronomic performance.